comparemela.com
  1. Home
  2. Live Updates
  3. Michael Lichtenberg - Breaking News

Latest Breaking News On - Michael lichtenberg - Page 2 : comparemela.com

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

The spiky stent may limit vessel recoil and improve drug delivery, but it’s still too early for strong conclusions, says Sahil Parikh.

New zealandBad krozingenBaden wübergNordrhein westfalenNew yorkUnited statesHerzzentrum freiburgThomas zellerMichael lichtenbergSahil parikhPresbyterian columbia university irving medical centerMd vascular centre clinic arnsbergVascular centre clinic arnsbergReflow medicalHerzzentrum freiburg bad krozingenColumbia university irving medical center

Second Round of Late-Breaking Clinical Trial Results Announced at VIVA22

/PRNewswire/ The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and.

Thomas maldonadoPetera soukasWynn las vegasMichael lichtenbergIdo weinbergDaniel clairPrakash krishnanPenumbra incGore associatesLimflow incSociety for vascular surgeryLate breaking clinical trialsWynn lasVascular interventional advancesYear resultsStent graft

VIVA Foundation Symposium presents Clinical Trial Findings

The second round of late-breaking clinical trial results were presented at VIVA22 on Nov. 1 in Las Vegas, NV.

Thomas maldonadoPetera soukasMichael lichtenbergIdo weinbergDaniel clairPrakash krishnanLas vegasPenumbra incGore associatesLimflow incSociety for vascular surgeryVascular interventional advancesYear resultsSuperficial femoral arterySingle arm studyPatient reported quality

First Round of Late-Breaking Clinical Trial Results Announced at VIVA22

/PRNewswire/ The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and.

United statesKenneth rosenfieldWynn las vegasMichael lichtenbergMehdi shishehborEhrinj armstrongSean lydenPeripheral academic research consortiumSurmodics incJournal of the american college cardiologyLate breaking clinical trialsWynn lasVascular interventional advancesPropensity adjusted comparisonDrug coated balloons versus bare metal stentsFemoropopliteal lesions

First Round of Late-Breaking Clinical Trial Results Announced at VIVA22

/PRNewswire/ The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and.

United statesKenneth rosenfieldWynn las vegasMichael lichtenbergMehdi shishehborEhrinj armstrongSean lydenPeripheral academic research consortiumSurmodics incJournal of the american college cardiologyLate breaking clinical trialsWynn lasVascular interventional advancesPropensity adjusted comparisonDrug coated balloons versus bare metal stentsFemoropopliteal lesions

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.